Sold as Aemcolo. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Rifamycin Sodium (sold as Aemcolo), first approved Nov 16, 2018, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Aemcolo | Part D | $0K | -100% | 0 |
| Fecal Microbiota Transplantation for the Treatment of Refractory Hepatic Encephalopathy After TIPS SurgeryHepatic Encephalopathy, Fecal Microbiota Transplantation · Air Force Military Medical University, China | Early phase 1 | Recruiting | Jul 6, 2026 |
| Evaluation of the Outcome of Fecal Microbiota TransplantationHepatic Encephalopathy, Fecal Microbiota Transplantation · Air Force Military Medical University, China | Phase 1 / Phase 2 | Not yet recruiting | Mar 6, 2026 |
| Drug-drug Interaction Study of Rifampin and Anaprazole SodiumDrug-drug Interaction Study · Xuanzhu Biopharmaceutical Co., Ltd. | Phase 4 | Not yet recruiting | Jan 9, 2026 |
| Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection FractionBacterial Overgrowth Syndrome Small Bowel, Heart Failure with Preserved Ejection Fraction · I.M. Sechenov First Moscow State Medical University | Not applicable | Recruiting | Oct 22, 2024 |
| The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot StudyPulmonology · National Taiwan University Hospital | Phase 4 | Recruiting | Oct 20, 2022 |
| Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) TrialDiverticulitis · University of Washington | Not applicable | Active, not recruiting | Sep 19, 2019 |
| Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBILatent Tuberculosis · Centers for Disease Control and Prevention | Phase 2 / Phase 3 | Recruiting | Mar 22, 2018 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 16, 2018 | AemcoloNDA 210910 · New molecular entity | Cosmo Technologies | 1 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA